Rachel Wade

4.7k total citations · 1 hit paper
64 papers, 2.9k citations indexed

About

Rachel Wade is a scholar working on Public Health, Environmental and Occupational Health, Pediatrics, Perinatology and Child Health and Pathology and Forensic Medicine. According to data from OpenAlex, Rachel Wade has authored 64 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Public Health, Environmental and Occupational Health, 22 papers in Pediatrics, Perinatology and Child Health and 17 papers in Pathology and Forensic Medicine. Recurrent topics in Rachel Wade's work include Acute Lymphoblastic Leukemia research (29 papers), Childhood Cancer Survivors' Quality of Life (22 papers) and Chronic Lymphocytic Leukemia Research (16 papers). Rachel Wade is often cited by papers focused on Acute Lymphoblastic Leukemia research (29 papers), Childhood Cancer Survivors' Quality of Life (22 papers) and Chronic Lymphocytic Leukemia Research (16 papers). Rachel Wade collaborates with scholars based in United Kingdom, Mexico and United States. Rachel Wade's co-authors include Ajay Vora, Rachael Hough, Nick Goulden, Chris Mitchell, Sue Richards, Jeremy Hancock, Clare Rowntree, Anthony V. Moorman, Daniel Catovsky and Monica Else and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Rachel Wade

62 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial

2013 313 citations Ajay Vora, Nick Goulden et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rachel Wade United Kingdom	25	1.4k	1.1k	963	918	902	64	2.9k
Evarist Feliú Spain	30	721 0.5×	978 0.9×	1.3k 1.4×	386 0.4×	675 0.7×	209	3.0k
M Zimmermann Germany	29	2.3k 1.7×	348 0.3×	2.3k 2.3×	1.1k 1.2×	341 0.4×	61	3.7k
Alan Lichtin United States	27	771 0.6×	1.0k 1.0×	1.9k 2.0×	363 0.4×	423 0.5×	101	3.8k
Ian M. Franklin United Kingdom	27	1.4k 1.0×	478 0.4×	2.0k 2.1×	438 0.5×	200 0.2×	77	3.3k
Erik Forestier Sweden	36	2.9k 2.1×	378 0.4×	2.3k 2.3×	1.5k 1.6×	275 0.3×	109	4.2k
Mathilde Hunault France	27	653 0.5×	519 0.5×	1.3k 1.4×	242 0.3×	333 0.4×	111	2.2k
Véronique Lhéritier France	20	1.9k 1.4×	269 0.3×	1.6k 1.6×	674 0.7×	247 0.3×	44	2.4k
David K. Kalwinsky United States	28	1.9k 1.3×	350 0.3×	1.6k 1.7×	703 0.8×	206 0.2×	70	3.0k
Matthew D. Seftel Canada	24	401 0.3×	289 0.3×	741 0.8×	189 0.2×	326 0.4×	111	1.6k
F R Appelbaum United States	25	452 0.3×	479 0.4×	2.2k 2.3×	216 0.2×	408 0.5×	47	3.0k

Countries citing papers authored by Rachel Wade

Since Specialization

Citations

This map shows the geographic impact of Rachel Wade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel Wade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel Wade more than expected).

Fields of papers citing papers by Rachel Wade

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel Wade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel Wade. The network helps show where Rachel Wade may publish in the future.

Co-authorship network of co-authors of Rachel Wade

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel Wade. A scholar is included among the top collaborators of Rachel Wade based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel Wade. Rachel Wade is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Berúmen, Jaime, Jason Torres, Jesús Alegre-Díaz, et al.. (2025). Polygenic prediction of coronary heart disease among 130 000 Mexican adults. European Journal of Preventive Cardiology. 33(3). 415–423.

Alegre-Díaz, Jesús, Fiona Bragg, Eirini Trichia, et al.. (2023). Educational and social inequalities and cause-specific mortality in Mexico City: a prospective study. The Lancet Public Health. 8(9). e670–e679. 10 indexed citations

Bragg, Fiona, Pablo Kuri‐Morales, Jaime Berúmen, et al.. (2023). Diabetes and infectious disease mortality in Mexico City. BMJ Open Diabetes Research & Care. 11(2). e003199–e003199. 3 indexed citations

Gnatiuc, Louisa, Rachel Wade, Jesús Alegre-Díaz, et al.. (2023). Body Composition and Risk of Vascular‐Metabolic Mortality Risk in 113 000 Mexican Men and Women Without Prior Chronic Disease. Journal of the American Heart Association. 12(3). e028263–e028263. 3 indexed citations

Alegre-Díaz, Jesús, Louisa Gnatiuc, Raúl Ramírez-Reyes, et al.. (2022). Body mass index and COVID-19 mortality: prospective study of 120 000 Mexican adults. International Journal of Epidemiology. 51(5). 1698–1700. 2 indexed citations

Gnatiuc, Louisa, Roberto Tapia‐Conyer, Rachel Wade, et al.. (2021). Abdominal and gluteo-femoral markers of adiposity and risk of vascular-metabolic mortality in a prospective study of 150 000 Mexican adults. European Journal of Preventive Cardiology. 29(5). 730–738. 10 indexed citations

Alegre-Díaz, Jesús, William G. Herrington, Natalie Staplin, et al.. (2021). Association of Kidney Function With NMR-Quantified Lipids, Lipoproteins, and Metabolic Measures in Mexican Adults. The Journal of Clinical Endocrinology & Metabolism. 106(10). 2828–2839. 9 indexed citations

Thomson, Blake, Roberto Tapia‐Conyer, Ben Lacey, et al.. (2021). Low-intensity daily smoking and cause-specific mortality in Mexico: prospective study of 150 000 adults. International Journal of Epidemiology. 50(3). 955–964. 9 indexed citations

Rowe, Penny M., Timothy L. Guasco, Grace Y. Stokes, et al.. (2020). Integrating polar research into undergraduate curricula using computational guided inquiry. Journal of Geoscience Education. 69(2). 178–191. 2 indexed citations

10.

O’Connor, David, Amir Enshaei, Jack Bartram, et al.. (2017). Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 36(1). 34–43. 99 indexed citations

11.

Bartram, Jack, Rachel Wade, Ajay Vora, et al.. (2016). Excellent outcome of minimal residual disease-defined low-risk patients is sustained with more than 10 years follow-up: results of UK paediatric acute lymphoblastic leukaemia trials 1997–2003. Archives of Disease in Childhood. 101(5). 449–454. 22 indexed citations

12.

Russell, Lisa J., Amir Enshaei, Lisa Jones, et al.. (2014). IGH @ Translocations Are Prevalent in Teenagers and Young Adults With Acute Lymphoblastic Leukemia and Are Associated With a Poor Outcome. Journal of Clinical Oncology. 32(14). 1453–1462. 57 indexed citations

13.

Patrick, Katharine, Rachel Wade, Nicholas Goulden, et al.. (2014). Improved Outcome for Children and Young People with T-Acute Lymphoblastic Leukaemia: Results of the UKALL 2003 Trial. Blood. 124(21). 3702–3702. 12 indexed citations

14.

Vora, Ajay, Nick Goulden, Chris Mitchell, et al.. (2014). Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. The Lancet Oncology. 15(8). 809–818. 192 indexed citations

15.

Vora, Ajay, Nick Goulden, Rachel Wade, et al.. (2013). Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. The Lancet Oncology. 14(3). 199–209. 313 indexed citations breakdown →

16.

Lin, Ke, Janet Adamson, Gillian G. Johnson, et al.. (2012). Functional Analysis of the ATM-p53-p21 Pathway in the LRF CLL4 Trial: Blockade at the Level of p21 Is Associated with Short Response Duration. Clinical Cancer Research. 18(15). 4191–4200. 26 indexed citations

17.

Else, Monica, Kim Cocks, Rachel Wade, et al.. (2011). Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial. Leukemia & lymphoma. 53(7). 1289–1298. 16 indexed citations

18.

Else, Monica, Alastair G. Smith, Kim Cocks, et al.. (2008). Patients’ experience of chronic lymphocytic leukaemia: baseline health‐related quality of life results from the LRF CLL4 trial. British Journal of Haematology. 143(5). 690–697. 40 indexed citations

19.

Dearden, Claire, Rachel Wade, Monica Else, et al.. (2007). The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood. 111(4). 1820–1826. 92 indexed citations

20.

Catovsky, Daniel, Estella Matutes, Martin J.S. Dyer, et al.. (2007). Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. The Lancet. 370(9583). 230–239. 482 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact